Early lymph node check is saving lives in melanoma patients

Early lymph node check is saving lives in melanoma patients

19 October 2017

Research presented this week at the 9th World Congress of Melanoma supports the updated guideline recommendation that sentinel lymph node biopsy be performed in more patients newly diagnosed with melanoma, as it has the potential to save lives due to the information the procedure provides.

This biopsy, which looks for cancer cells in the lymph nodes, can identify patients whose melanoma has spread beyond the site on the skin (Stage III melanoma) and who may be suitable to receive the new generation of anti-melanoma drugs.

The recently published Australian Clinical Practice Guidelines for the Diagnosis and Management of Melanoma recommends that “sentinel lymph node biopsy should be considered for all patients with melanoma greater than 1 mm in thickness and for patients with melanoma greater than 0.8 mm with other high risk pathological features to provide optimal staging and prognostic information and to maximise management options for patients who are node positive”.

“We know patients who have melanoma cells present in their draining lymph nodes (Stage III) are up to three times more likely to die from their melanoma than patients where the lymph nodes are clear,” says David Gyorki, a consultant surgeon and melanoma specialist at the Peter MacCallum Cancer Centre.

“For some time, we’ve known that sentinel lymph node biopsy is an excellent way to identify those patients who have a higher risk of having their disease progress, and with the new drugs we have gained the tools to respond and to reduce this risk.

“On the horizon, we will have access to effective, well tolerated drug therapies that can reduce the risk of relapse and, using sentinel lymph node biopsy to identify appropriate patients, the data indicate that this strategy is saving lives.”

For most patients diagnosed with melanoma, their disease is localised and effectively treated with surgery; however, some patients’ disease will progress. Of the 14,000 Australians diagnosed with melanoma each year, almost 15% will die from their disease.

Findings from recent clinical trials have demonstrated a major improvement in survival for patients with Stage III melanoma using drug therapy after surgery with the aim to prevent the melanoma from appearing in distant organs (Stage IV disease).

In one such clinical trial, known as COMBI-AD, patients who received a combination of targeted therapies (dabrafenib and trametinib) decreased the chance of their melanoma progressing by 53% compared to the current standard therapy of ‘watch and wait’.

“We encourage clinicians to inform their patients about sentinel lymph node biopsy so that patients can properly understand their risk of recurrence and death from melanoma, and therefore discuss the option of further drug therapy” says Professor Georgina Long, Medical Oncologist and Co-Medical Director of Melanoma Institute Australia.

The 9th World Congress of Melanoma is underway in Brisbane, October 18 – 21.

International collaboration the key to increasing survival
24 Oct 2018

International collaboration the key to increasing survival

"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.

High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration
23 Oct 2018

High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration

Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.

Monthly dose of immunotherapy allows flexibility for patients undergoing treatment
11 Oct 2018

Monthly dose of immunotherapy allows flexibility for patients undergoing treatment

A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.

Australia's best minds in melanoma research converge on Melbourne
08 Oct 2018

Australia's best minds in melanoma research converge on Melbourne

The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.

Nobel Prize for novel cancer therapies
04 Oct 2018

Nobel Prize for novel cancer therapies

The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.

World Health Organisation launches 4th edition of Classification of Skin Tumours
31 Aug 2018

World Health Organisation launches 4th edition of Classification of Skin Tumours

The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.

Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal
31 Aug 2018

Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal

Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.

Support PBS listing for pembrolizumab
23 Aug 2018

Support PBS listing for pembrolizumab

Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.

World Congress on Cancers of the Skin 2018
17 Aug 2018

World Congress on Cancers of the Skin 2018

The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.

Melanoma Institute Australia welcomes new CEO Matthew Browne
09 Aug 2018

Melanoma Institute Australia welcomes new CEO Matthew Browne

Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).

Melanoma in Practice: Nurse Conference
26 Jul 2018

Melanoma in Practice: Nurse Conference

It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’. 

Reducing the risk of melanoma in young adults
19 Jul 2018

Reducing the risk of melanoma in young adults

A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.

Melanoma Institute Australia launches free e-learning education portal
20 Jun 2018

Melanoma Institute Australia launches free e-learning education portal

Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.

David Day and a lifetime of missed moments
08 Jun 2018

David Day and a lifetime of missed moments

When David lost his life last year, he was 33, with three daughters under six.

Australian melanoma experts share latest breakthroughs with world's best oncologists
06 Jun 2018

Australian melanoma experts share latest breakthroughs with world's best oncologists

ASCO 2018 brings together the world's best in oncology from around the world. 

ASCO 2018 – the important role of clinical trials
06 Jun 2018

ASCO 2018 – the important role of clinical trials

Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.

MIA Scoops Awards at the International Academy of Pathology
04 Jun 2018

MIA Scoops Awards at the International Academy of Pathology

Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology. 

Updated Clinical Guidelines for Melanoma
25 May 2018

Updated Clinical Guidelines for Melanoma

Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.

Melanoma and Marital Status: A Study
11 May 2018

Melanoma and Marital Status: A Study

An American study has discovered a link between early detection and marital status in melanoma diagnosis. 

A weekend in Paris talking all things pathology...
02 May 2018

A weekend in Paris talking all things pathology...

An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.